Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-11-01
2005-11-01
Priebe, Scott D. (Department: 1632)
Chemistry: molecular biology and microbiology
Vector, per se
C435S325000, C435S455000, C435S456000, C424S093200, C424S093210, C536S023400, C536S023530
Reexamination Certificate
active
06960469
ABSTRACT:
Genetically modified cell implant comprising an exogenous nucleotide sequence coding for all or part of an antibody, method for the preparation of such an implant and its therapeutic use for the treatment or prevention of an acquired disease. The invention also concerns an adenoviral vector, a pharmaceutical composition and its therapeutic use.
REFERENCES:
patent: 5219740 (1993-06-01), Miller et al.
patent: 5314995 (1994-05-01), Fell, Jr. et al.
patent: 6159947 (2000-12-01), Schweighoffer et al.
patent: 6294377 (2001-09-01), Haddada et al.
patent: 2706486 (1994-12-01), None
patent: 90/01550 (1990-02-01), None
patent: 92/15676 (1992-09-01), None
patent: 93/03143 (1993-02-01), None
patent: 94/06920 (1994-03-01), None
patent: 94/10323 (1994-05-01), None
patent: 94/19017 (1994-09-01), None
Berkner, K.L. “Expression of heterologous sequences in adenoviral vectors,” Curr. Top. Microbiol. Immunol. 158: 39-66, 1992.
Berkner, K.L., “Expression of heterologous sequences in adenoviral vectors,” Curr. Top. Microbiol. Immunol. 158:39-66, 1992.
Kolls et al., “Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer,” Proc. Natl. Acad. Sci. USA 91: 215-219, Jan. 1994.
Chen et al., “Intracellular Antibodies as a New Class of Therapeutic Molecules for Gene Therapy”, Human Gene Therapy, (1994), vol. 5, No. 5, pp. 595-601, New York, NY, Mary Ann Liebert Inc., Los Angeles, USA.
D. Moritz et al, “Cytotoxic T Lymphocytes With a Grated Recognition Specificity for ERBB2-Expressing Tumor Cells”, Proceedings of the National Academy of Science of the USA, May 1994, pp. 4318-4322, vol. 91, No. 10, 10 Washington, D.C., USA.
A. Conley et al., “Neutralization of Divergent Human Immunodeficiency Virus Type 1 Variants and Primary Isolates by IAM-41-2F5, an Anti-gp41 Human Monoclonal Antibody”, Proceedings of the National Academy of Sciences, Apr. 1994, pp. 3348-3352, vol. 91, No. 8, 12 Washington D.C..
M. Rosenfeld et al., “E1-E3 Replication Deficient Recombinant Adenovirus Vector Containing the Human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) cDNA Does Not Replicate in Human Respiratory Epithelial Cells” Journal of Cellular Biochemistry, Supplement, Apr. 1993, p. 251, No. 17, Part E, 29-25 New York, NY, USA.
Crystal, R.G., Science, vol. 270, pp. 404-410, (1995), AAAS, Washington D.C., USA.
Orkin et al. NIH Report on the Investment in Research on Gene Therapy, (Dec. 1995), NIH, USA.
Verma et al., Nature, vol. 389, pp. 239-242, (Sep. 1997), MacMillin, London.
Anderson, W.F., Nature, vol. 392, Suppl. pp. 25-30, (Apr. 1998).
Brinkmann et al., Proc. Natl. Acad. Sci., U.S.A., vol. 88, pp. 8616-8620, (Oct. 1991).
Batra et al., Molecular and Cellular Biology, vol. 11(4): pp. 2200-2205.
Chaudhary et al. Proc. Natl. Acad. Sci., U.S.A., vol. 87, pp. 9491-9494, (Dec. 1990).
Marshall, E.M., Science, vol. 269, pp. 1050-1055, (Aug. 1995).
Leroy Pierre
Mehtali Majid
Burns Doane , Swecker, Mathis LLP
Priebe Scott D.
Transgene S.A.
LandOfFree
Adenoviral vectors encoding an antibody fused to a CD4... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenoviral vectors encoding an antibody fused to a CD4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenoviral vectors encoding an antibody fused to a CD4... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3457806